ABILIFY 2 MG
ARIPIPRAZOLE : 2 MG · DIN 02322374 · OTSUKA PHARMACEUTICAL CO LTD
Health Canada status: MARKETED
What is ABILIFY?
ABILIFY 2 MG contains ARIPIPRAZOLE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02322374, held by OTSUKA PHARMACEUTICAL CO LTD, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Mar-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ABILIFY used for?
ABILIFY (aripiprazole) is indicated for: the treatment of schizophrenia and related psychotic disorders in adults. In controlled clinical trials, ABILIFY was found to improve both positive and negative symptoms. ABILIFY has been shown to be more effective than placebo in maintaining clinical improvement for up to 26 weeks in adults. ABILIFY is also indicated for the treatment of manic or mixed episodes in bipolar I disorder in adults. ABILIFY may be used as acute monotherapy or cotherapy with lithium or divalproex sodium when there is an insufficient acute response to these agents alone. ABILIFY as cotherapy with lithium or divalproex sodium has been shown to be more effective than placebo plus mood stabilizer in maintaining clinical improvement for up to 1 year in adult patients with manic or mixed episodes associated with bipolar I disorder. Additionally, ABILIFY is indicated for use as an adjunct to antidepressants for the treatment of Major Depressive Disorder (MDD) in adult patients who had an inadequate response to prior antidepressant treatments during the current episode.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02322374 |
|---|---|
| Brand name | ABILIFY |
| Generic / active ingredient | ARIPIPRAZOLE : 2 MG |
| Manufacturer | OTSUKA PHARMACEUTICAL CO LTD |
| Strength | 2 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AX12 ARIPIPRAZOLE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Mar-2018 |
How is it stored and handled?
null
How is it supplied?
2 mg, 5 mg, 10 mg: Bottles of 30 tablets and blister packs of 100 tablets*. 15 mg: Bottle of 30 tablets and blister packs of 100 tablets*. Further package sizes not specified in the monograph.
What can be used instead?
Other Canadian products sharing ATC code N05AX12 ARIPIPRAZOLE. 83 of 105 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ABILIFY | 10 MG | TABLET | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02322390 |
| ABILIFY | 15 MG | TABLET | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02322404 |
| ABILIFY | 20 MG | TABLET | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02322412 |
| ABILIFY | 30 MG | TABLET | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02322455 |
| ABILIFY | 5 MG | TABLET | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02322382 |
| ABILIFY ASIMTUFII | 720 MG / 2.4 ML | SUSPENSION (EXTENDED-RELEASE) | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02554569 |
| ABILIFY ASIMTUFII | 960 MG / 3.2 ML | SUSPENSION (EXTENDED-RELEASE) | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02554577 |
| ABILIFY MAINTENA | 300 MG | KIT ; POWDER FOR SUSPENSION, SUSTAINED-RELEASE | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02420864 |
| ABILIFY MAINTENA | 400 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | OTSUKA PHARMACEUTICAL CO LTD | MARKETED | DIN 02420872 |
| AG-ARIPIPRAZOLE | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02448203 |
Who else supplies ARIPIPRAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ARIPIPRAZOLE appears in 791 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.